Perspective Therapeutics (CATX) vs Cumberland Pharmaceuticals (CPIX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cumberland Pharmaceuticals (CPIX) has outperformed Perspective Therapeutics (CATX) over the past year, gaining 193.5% versus a loss of 63.9%. Over five years, CPIX leads with a +161.9% price change compared with -84.6% for CATX. Perspective Therapeutics is the larger company by market cap ($91.0 million vs $87.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CATX | CPIX |
|---|---|---|
| Share price | $0.7538 | $5.84 |
| Market cap | $91.03M | $87.57M |
| 1-day change | -3.85% | -7.30% |
| YTD return | -72.59% | +46.73% |
| 1-year return | -63.93% | +193.47% |
| 5-year return | -84.62% | +161.88% |
| Forward P/E | — | 41.71 |
| EPS (TTM) | $-1.25 | $-0.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $44.52M |
| Revenue growth (YoY) | — | +17.57% |
| Net income (latest FY) | $-103.12M | $-2.84M |
| Gross margin | — | 85.02% |
| Operating margin | — | -6.27% |
| Net margin | — | -6.37% |
| 52-week high | $6.16 | $9.28 |
| 52-week low | $0.73 | $2.00 |
| Distance from 52-week high | -87.76% | -37.07% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +1188.14% | — |
| Average volume | 2.70M | 114.52K |
| Shares outstanding | 120.76M | 15.00M |
| Employees | 163 | 88 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CPIX has outperformed CATX by 257.4 percentage points over the past year.
About Perspective Therapeutics
CATX stock →Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.
Health Care · Biotechnology: Pharmaceutical Preparations · 163 employees
About Cumberland Pharmaceuticals
CPIX stock →Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H.
Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees
CATX vs CPIX FAQ
Which is bigger, Perspective Therapeutics or Cumberland Pharmaceuticals?
Perspective Therapeutics (CATX) is larger, with a market capitalization of $91.03M compared with $87.57M for Cumberland Pharmaceuticals (CPIX).
Which stock has performed better over the past year, CATX or CPIX?
CPIX returned +193.47% over the past 12 months, compared with -63.93% for CATX (price return, excluding dividends). Past performance does not predict future results.
Are Perspective Therapeutics and Cumberland Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.